Analytical Data
-
Gene name
MAP2K7
- Application
-
Alternative Names
Jnkk2; MAPKK7; MKK7; PRKMK7; SKK4; JNK-activating kinase 2; Stress-activated protein kinase kinase 4; c-Jun Nterminal kinase kinase 2
-
Species
Human
-
Source
E. coli
-
Tag
N-6His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14733
-
Expression Region
113-388aa
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
MAP2K7, also known as JNK kinase or MKK7, is a vital component of the mitogen-activated protein kinase (MAPK) signaling cascade, specifically involved in the activation of c-Jun N-terminal kinases (JNKs). This pathway plays a crucial role in cellular responses to various stress stimuli, including inflammation, apoptosis, and cell proliferation. Due to its significant involvement in these processes, MAP2K7 has garnered considerable interest in cancer research, neurodegenerative diseases, and other pathologies. Studies have shown that dysregulation of the MAPK pathway, including MAP2K7, is linked to tumor progression and metastasis, making it a potential target for therapeutic interventions. The recombinant expression of MAP2K7 allows for in-depth studies of its biochemical properties, substrate interactions, and regulatory mechanisms. Furthermore, producing MAP2K7 as a recombinant protein facilitates the exploration of its role in various signaling pathways under controlled experimental conditions. This, in turn, aids in understanding its functional implications in health and disease, leading to potential approaches for targeted therapies. Understanding the structure-function relationship of MAP2K7 through recombinant protein studies may open new avenues for drug design, particularly in targeting specific pathways influenced by JNK signaling in diseases such as cancer and chronic inflammatory conditions. Overall, the investigation of recombinant MAP2K7 holds the promise of elucidating its precise biological roles and therapeutic potential in various diseases.
